Drugs / Namilumab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02354599 | Nov 2014 → May 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01317797 | Mar 2011 → Aug 2013 | rheumatoid arthritis | Takeda | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05314517 | Aug 2022 → Oct 2024 | pulmonary sarcoidosis | Kinevant Sciences GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT05351554 | Aug → Nov 2022 | cardiac sarcoidosis | Kinevant Sciences GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT03622658 | Sep 2018 → Feb 2020 | spondyloarthropathy | Izana Bioscience Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02379091 | Dec 2014 → May 2016 | rheumatoid arthritis | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT02129777 | Jun 2014 → Sep 2015 | psoriasis | Takeda | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02393378 Comparator | Apr 2015 → Jun 2016 | rheumatoid arthritis | Takeda | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Namilumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05314517 ↗ |
| Known as | AMG203 | “OBJECTIVES: To investigate the clinical use of GM-CSF neutralization by evaluating the efficacy and safety of namilumab (AMG203), a monoclonal antibody GM-CSF inhibitor, in...” PMID 30207587 ↗ Nov 20182“BACKGROUND: Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF)” PMID 30999929 ↗ Apr 2019 “Namilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity to the GM-CSF ligand.” PMID 28274253 ↗ Mar 2017 |
| Known as | Anti-hgm-csf igg1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743044 ↗ |
| Known as | MT203 | “Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.” NCT01317797 ↗ |
| Action | Inhibit | “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL1743044 ↗1“a monoclonal antibody GM-CSF inhibitor” PMID 30207587 ↗ Nov 2018 |
| Modality | Monoclonal antibody | “Namilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity to the GM-CSF ligand.” PMID 28274253 ↗ Mar 2017 |
| Route | Subcutaneous | “administered three times, subcutaneous in the abdomen” NCT01317797 ↗ |
| Target | CSF2 | “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL1743044 ↗ |